AstraZeneca AZN announced that the FDA has accepted a regulatory filing seeking to expand the use of its blockbuster rare ...

AstraZeneca's CEO shared a rare, testable claim about AI with CNBC.

AstraZeneca’s SOUNDTRACK-F1 study aims to improve on related risks seen with chemotherapy-including treatments in follicular ...

AstraZeneca (LSE:AZN) is advancing its oral GLP-1 candidate elecoglipron into Phase 3 trials after positive Phase 2b results.

AstraZeneca has some exciting things going on... AstraZeneca currently has three programs targeting diabetes and obesity care. During the ObesityWeek conference earlier this month, management provided ...

If the Phase III trials of the oral GLP-1RA are successful, AstraZeneca is set to join a fast-growing market.

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

AstraZeneca is emerging as a potential new contender in the booming obesity treatment market after its experimental ...

The LinkedIn activities of AstraZeneca employees have yet again landed the drugmaker in hot water, with the U.K. marketing ...

U.K.-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is making news, but not in a good way. Its operations in China were recently rocked when Leon Wang, the company's president in the country -- ...

AstraZeneca (NASDAQ:AZN) (LSE:AZN) trades at a premium to most of its big-pharma peers, with the exception of weight-loss giants Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). However, I’m bullish ...

Medications used to treat diabetes and obesity are the hottest commodities in healthcare right now. Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound have all become blockbuster ...